ABSTRACT
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. (1, 2) Bone marrow (BM) involvement by DLBCL, assessed by random iliac crest bone marrow biopsy (BMB), can be identified in up to one quarter of newly diagnosed patients and is associated with poor outcomes.(3-6) For many decades, BMB has been the gold standard test to detect bone marrow involvement, and a mandatory component of the routine staging work-up for DLBCL.
18F-fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET/CT) is now recommended as a standard staging investigation of FDG-avid aggressive lymphomas, including DLBCL. (7) In Hodgkin lymphoma (HL), routine BMB can erroneously miss BM involvement in patients with FDG-avid patchy lesions outside the biopsy area. (8) However, the occasionally missed BM involvement by PET/CT rarely alters HL prognosis or management since almost all of these patients already present with advanced stage according to PET/CT alone.(9,10) Therefore, BMB is no longer considered necessary in the routine staging of HL. (7) In DLBCL, studies evaluating the role of BMB and PET/CT in the staging of the BM have been less consistent. In some studies, PET/CT accurately identified BM involvement, (11) (12) (13) while in others, it was often missed by PET/CT. (14, 15) Furthermore, in contrast to HL, patients with DLBCL frequently have discordant involvement of the BM by an indolent non-Hodgkin lymphoma (iNHL). (3) (4) (5) (6) For these reasons, recent guidelines recommending against routine BMB for all PET/CT-staged patients with DLBCL(7) have been controversial.(16) Therefore, we undertook a large-scale study Danish-Canadian study to quantify the added diagnostic value of routine BMB in patients with newly diagnosed DLBCL undergoing PET/CT staging.
METHODS

Patient Identification
This is a retrospective study of patients with newly-diagnosed DLBCL from the academic centers of the British Columbia Cancer Agency (BCCA), Aalborg, and Copenhagen (Rigshospitalet). Patients with treatment-naïve DLBCL who underwent staging PET/CT and unilateral iliac crest BMB were identified through queries in the BCCA Lymphoid Cancer Database and the national Danish Lymphoma Registry (LYFO). These databases have been described in detail previously. (17, 18) Baseline clinical and pathological characteristics were retrieved from these databases and missing information was collected from individual medical records whenever possible. Original PET/CT and pathology reports were reviewed by a local investigator for disease stage, sites of extranodal involvement, diagnostic biopsy results, and BM histology. Patients with a previous diagnosis of iNHL and those with composite histology in the diagnostic biopsies were excluded.
PET/CT Imaging and Reporting
PET/CT scans were performed locally on dedicated machines and in accordance with manufacturer guidelines. The CT component of the PET/CT was diagnostic (e.g., contrastenhanced) unless a diagnostic CT was performed separately in addition to the PET/CT. In the latter case, a low-dose CT was performed for attenuation correction.
Original staging PET/CT reports were reviewed for the presence of FDG-avid lesions in bone/bone marrow suggestive of lymphomatous infiltration and their number (unifocal=1, bifocal=2, multifocal>2). CT reports were reviewed for the presence of bone abnormalities (osteolytic and/or osteosclerotic) corresponding to the areas of abnormal skeletal FDG uptake.
Areas of focally increased FDG-uptake in bone and/or BM were considered positive for BM involvement by lymphoma unless definitively explained by an alternate cause. A distinction between cortical bone and BM involvement was not made given the possibility of small spatial misalignments between CT and PET fusions, and the absence of cortical bone involvement in patients without increased FDG uptake in the marrow space, as previously reported. (12) 
Bone Marrow Biopsy
In all three institutions, blind unilateral posterior iliac crest trephine biopsy and aspirate were performed routinely upon diagnosis of DLBCL. Cases were reported locally by dedicated hematopathologists. The diagnosis of lymphoma was based on standard morphology and immunohistochemistry. Flow cytometry was available at all centers and was performed routinely or at the discretion of the hematopathologist. Fluorescent in-situ hybridization was performed according to institutional guidelines or if deemed necessary by the hematopathologist.
All patients were considered to have an adequate BMB as determined by the hematopathologist.
The length of the BM core was not collected.
Statistical Analysis
Baseline characteristics were described using summary statistics. Ann Arbor stage was determined using PET/CT with and without the contribution of BMB, and the proportion of stage IV cases by each method was calculated. (19, 20) The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each approach were computed.
Overall survival (OS) was defined as the time from diagnosis of DLBCL to death from any cause or date of last follow-up alive. Progression-free survival (PFS) was defined as the time from diagnosis of DLBCL to first relapse or progression, death from any cause, or last follow-up. OS and PFS were estimated using the Kaplan-Meier method, and differences between groups were compared using the log-rank test. (21) Cox proportional hazard models were constructed to evaluate the impact of PET/CT and BMB 
Outcomes
With a median follow up of 2 years (range 3 months -6.5 years) in living patients, the 2-year OS and PFS were 79% (95% confidence interval [CI] 75%, 83%) and 74% (95% CI 70%, 78%), respectively. There was no difference in OS (p=0.319) or PFS (p=0.186) between the three treatment centers, enabling pooling of data for the present analysis.
In the 256 patients with stage IV, 2-year OS was 79% (95% CI 71%, 87%) for those with negative PET/CT for BM involvement (n=126) and 63% (95% CI 53%, 73%) for those with positive (n=130) PET/CT (p=0.001). The 2-year PFS was 74% (95% CI 64%, 84%) and 53% (95% CI 43%, 63%), respectively (p<0.001). In stage IV (n=256) patients, 2-year OS was 82% (95% CI 72%, 92%) for those with negative PET/CT and BMB for bone/bone marrow involvement (n=91) and 65% (95% CI 57%, 73%) for those with positive (n=165) PET/CT or BMB (p=0.003). The 2-year PFS was 75% (95% CI 65%, 85%) and 57% (95% CI 49%, 65%), respectively (p=0.003). Kaplan-Meier curves are shown in Supplementary Figure S1 .
The 51 patients with concordant involvement of the BM experienced significantly worse outcomes than the 36 patients with discordant involvement or the 443 patients with no histological involvement of the BM. In multivariate analysis, concordant involvement of the BM was associated with worse OS and PFS compared to no histological BM involvement, while discordant involvement had OS and PFS similar to those with no BM involvement.
Characteristics and outcomes are summarized in Supplementary Table S4 PET/CT is unequivocally positive for BM involvement. On the other hand, if the PET/CT is negative for BM involvement, routine BMB is necessary to exclude concordant or discordant histology in the BM, which may only be relevant if it will affect patient management. (7) In theory, BMB may upstage some patients from early stage to advanced stage, can distinguish between indolent and aggressive histology in the marrow, and can add prognostic value. In our study, BMB upstaged 12 (6%) of patients with stage I/II who had a negative PET/CT for BM involvement. However, the majority had iNHL in the BM, and only 3 patients (1%) were Even though we aimed to include all patients with DLBCL during the study period, a small proportion at each center may not have had both PET/CT and BMB at diagnosis; for example, critically ill patients in need of immediate therapy. The degree to which their exclusion may have altered the comparison of test performance or outcomes is likely low, while the degree to which their exclusion increases the relevance of results to real-world clinical practice is very high.
PET/CT equipment, image acquisition, processing, and interpretation criteria evolved throughout the 6-year study period (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Therefore, intra and inter-observer variation may have altered the reliability of PET/CT interpretation. We did not collect standardized uptake values (SUV), again introducing subjectivity in the interpretation of scans. However, using semiquantitative measures like mean or maximum SUV requires a high degree of standardization, which often hampers external validity.
In conclusion, PET/CT accurately assessed BM involvement in the majority of patients with DLBCL. It is difficult to identify a subgroup of patients with negative PET/CT in whom treatment and prognosis would have been altered by BMB, as even in those with stage I/II by PET/CT, the likelihood of upstaging with a meaningful change in treatment is small. Even though discordant iNHL is missed without routine BMB, the favorable outcome of patients with discordant iNHL supports that they are managed safely with standard DLBCL therapy.
Diagnostically, BMB only minimally improved NPV after the findings on PET/CT scan were considered and did not lead to important changes in the distribution of IPI risk groups. Our data suggest routine BMB is not a critical element of disease staging in all patients with newly diagnosed DLBCL undergoing upfront PET/CT staging.
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